You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 kinase domain mutations

Showing 1 - 25 of 8,675
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)

Not yet recruiting
  • Lung Cancer, Non-squamous, Non-small Cell
  • (no location specified)
Nov 22, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

Active, not recruiting
  • HER2-positive Breast Cancer
  • PIK3CA analysis
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • Dnipro, Ukraine
  • +1 more
Jun 17, 2023

Breast Cancer Trial in Guangzhou (Take probiotics)

Recruiting
  • Breast Cancer
  • Take probiotics
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Mar 6, 2023

NSCLC Trial in Worldwide (Afatinib)

Completed
Has Results
  • NSCLC
  • Köln, Germany
  • +4 more
Aug 23, 2022

NSCLC Trial in Winter Haven (Poziotinib, Docetaxel)

Suspended
  • NSCLC
  • Winter Haven, Florida
    Bond Clinic, P.A.
Jan 27, 2023

Cyclin-dependent Kinase 4/6 Inhibitors on Body Composition in

Recruiting
  • Breast Cancer
  • CT scans
  • DEXA scan
  • Bronx, New York
    Montefiore Medical Center
Jan 6, 2023

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

HER2 Mutant NSCLC Trial (Pyrotinib maleate)

Not yet recruiting
  • HER2 Mutant Non-small Cell Lung Cancer
  • Pyrotinib maleate
  • (no location specified)
Jun 6, 2022

Recurrent/Advanced Gastric Cancer Trial in Seoul (Chemotherapy)

Not yet recruiting
  • Recurrent/Advanced Gastric Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 22, 2022

Pre-existing Kinase Domain Mutations in Ph-positive Leukemias

Recruiting
  • Leukemia
    • Vienna, Austria
      Medical Universitiy of Vienna
    Mar 23, 2021

    Among Talazoparib-Treated HER2-Negative mBC With gBRCA1/2m

    Completed
    • Metastatic Breast Cancer
    • Breast Neoplasms
    • New York, New York
      Pfizer Inc.
    Aug 5, 2022

    HR+, HER2-, Advanced Breast Cancer Trial (alpelisib)

    Available
    • HR+, HER2-, Advanced Breast Cancer
    • (no location specified)
    Jul 5, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    HER2/Neu+ Uterine Serous Carcinoma Trial in Tucson, New Haven, Boston (Afatinib)

    Recruiting
    • HER2/Neu+ Uterine Serous Carcinoma
    • Tucson, Arizona
    • +2 more
    Feb 2, 2022

    Tyrosine Kinase Inhibitors in Trastuzumab Emtansine Resistant

    Recruiting
    • Breast Cancer
    • Nanjing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Feb 7, 2022

    Homologous Recombination-related Genesmutationsand HRD in Breast

    Not yet recruiting
    • Breast Cancer
    • HER2-low Breast Cancer
    • Standard Management
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Jul 18, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Afatinib

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Afatinib Dimaleate
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Jun 28, 2022

    Breast Cancer Metastatic Trial in Beijing (TSL-1502 capsules(low dose), TSL-1502 capsules(high dose), Investigator's choice of

    Not yet recruiting
    • Breast Cancer Metastatic
    • TSL-1502 capsules(low dose)
    • +2 more
    • Beijing, China
      Cancer Hospital, Chinese Academy of Medical Sciences
    Jun 13, 2022

    Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

    Active, not recruiting
    • Metastatic Breast Cancer
    • Hospitalet de Llobregat, Barcelona, Spain
    • +6 more
    Jan 23, 2023

    Gene Mutations in Triple-negative and HER2+ Breast Cancer

    Active, not recruiting
    • Breast Cancer
      • Athens, Greece
        George Fountzilas
      Mar 15, 2022

      Early HER2-negative High-risk Breast Cancer and BRCA1/2

      Not yet recruiting
      • Breast Cancer
        • Arkhangelsk, Russian Federation
        • +19 more
        Jul 3, 2023

        HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer Trial in Spain (Olaparib)

        Recruiting
        • HER2-negative Breast Cancer
        • +2 more
        • Barcelona, Spain
        • +4 more
        Apr 14, 2022

        Tolerability Outcomes of Alpelisib in Real-world

        Recruiting
        • Breast Cancer
        • alpelisib plus fulvestrant
        • Mumbai, Maharashtra, India
        • +3 more
        Jun 8, 2022